Advances in therapeutic CRISPR/Cas9 genome editing
Достижения в терапевтическом редактировании генома с помощью CRISPR/Cas9
2015-09-26
SCID: 54.1/mndd8qu2
Discuss with AI
CRISPR/Cas9ex vivo stem cell editingguide RNA designin vivo disease allele modulationtherapeutic genome editing
Figures from the paper
Abstract (AI)
Targeted nucleases are widely used as tools for genome editing. Two years ago the clustered regularly interspaced short palindromic repeat (CRISPR)-associated Cas9 nuclease was used for the first time, and since then has largely revolutionized the field. The tremendous success of the CRISPR/Cas9 genome editing tool is powered by the ease design principle of the guide RNA that targets Cas9 to the desired DNA locus, and by the high specificity and efficiency of CRISPR/Cas9-generated DNA breaks. Several studies recently used CRISPR/Cas9 to successfully modulate disease-causing alleles in vivo in animal models and ex vivo in somatic and induced pluripotent stem cells, raising hope for therapeutic genome editing in the clinics. In this review, we will summarize and discuss such preclinical CRISPR/Cas9 gene therapy reports.
Key Findings
1
CRISPR/Cas9 generates DNA breaks with high specificity and efficiency, facilitating genome modification.
2
CRISPR/Cas9 has been applied ex vivo in somatic and induced pluripotent stem cells, supporting its therapeutic potential for clinical genome editing.
3
CRISPR/Cas9 has rapidly revolutionized genome editing since its first use two years prior, becoming a widely used targeted nuclease.
4
Recent preclinical studies have successfully used CRISPR/Cas9 to modulate disease-causing alleles in vivo in animal models.
5
The guide RNA design principle enables easy targeting of Cas9 to desired DNA loci, underpinning CRISPR/Cas9's success.
Research Object
Therapeutic CRISPR/Cas9 genome editing applications (preclinical gene therapy using CRISPR/Cas9 in vivo and ex vivo)
Research Subject
Use of CRISPR/Cas9 to modulate disease-causing alleles including specificity, efficiency, and preclinical therapeutic outcomes in animal models and somatic/induced pluripotent stem cells
Publication Details
Publication Date
2015-09-26
Journal
Publisher
ISSN
Cited by
276
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest